Surmodics (Surmodics) Cash-to-Debt

: 1.04 (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Surmodics's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.04.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Surmodics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Surmodics's Cash-to-Debt or its related term are showing as below:

SRDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.57 Med: No Debt Max: No Debt
Current: 1.04

During the past 13 years, Surmodics's highest Cash to Debt Ratio was No Debt. The lowest was 0.57. And the median was No Debt.

SRDX's Cash-to-Debt is ranked worse than
61.37% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs SRDX: 1.04

Surmodics Cash-to-Debt Historical Data

The historical data trend for Surmodics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Surmodics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash-to-Debt

No Debt

16.18

2.84

1.28

1.36

Surmodics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																0.78	0.57	1.33	1.36	1.04

Competitive Comparison

For the Medical Devices subindustry, Surmodics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Surmodics Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Surmodics's Cash-to-Debt falls into.

Surmodics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Surmodics's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	45.352	/	(0.872	+	32.379)
	=	1.36

Surmodics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	35.174	/	(0.997	+	32.879)
	=	1.04

Surmodics (NAS:SRDX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Surmodics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Surmodics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Surmodics (Surmodics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

SU6:Germany

Address

9924 West 74th Street, Eden Prairie, MN, USA, 55344

Website

https://www.surmodics.com

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

Executives

Jose H Bedoya	director
David Dantzker	other: See Explanation of Responses	80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr	director
Gary R Maharaj	director, officer: President & CEO	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich	officer: VP, Corp Dev & Strat Planning	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson	officer: General Manager
John D. Manders	officer: Corporate Controller	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber	officer: Sr. VP of Legal, GC and Sec.	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana	officer: VP, Clinical Affairs	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine	director	1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides	officer: Senior VP and CMO	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton	officer: VP of Research and Development	6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight	director	9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips	officer: Dep. Gen. Counsel & Corp. Sec.	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Timothy J. Arens	officer: General Manager - IVD	9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344